한글목차

세계의 AI 활용 Drug Discovery 및 임상시험 시장 규모는 2035년에 CAGR 24.1%로 성장할 것으로 예측됩니다.

의약품 개발 기간의 단축과 비용 효율화가 시장 발전을 촉진 :

AI 활용 Drug Discovery 및 임상시험 시장을 촉진하는 주요 요인에는 의약품 개발 기간의 단축, 연구 비용의 삭감, 업무 효율의 향상 등이 있습니다. AI 기술은 표적 발굴, 분자 스크리닝, 임상시험 최적화 등 신약개발의 다양한 단계를 간소화하여 보다 신속하고 비용효율적인 신약개발을 가능하게 합니다. 의약품 개발에 기여하고 있습니다. 또한 분자 설계를 위한 생성 모델과 환자 모집을 위한 예측 분석 등 AI 기반 플랫폼의 발전은 시장 성장을 더욱 촉진할 것으로 예상됩니다.

2025년 3월 24일, Oxford Drug Discovery Institute의 연구진은 알츠하이머병 치료제 개발을 가속화하기 위해 AI를 활용한 데이터베이스를 도입했습니다. 방대한 생의학 데이터를 효율적으로 분석하여 54개의 면역계 관련 유전자를 식별하고, 유전자 평가에 필요한 시간을 크게 단축하여 유망한 신약 타깃을 더 빨리 찾아낼 수 있었습니다.

2025년 3월 21일, 아스트라제네카는 베이징에 AI 및 데이터 사이언스 연구소를 갖춘 연구 및 제조 센터를 설립하기 위해 5년간 25억 달러를 투자할 것이라고 발표했습니다. 이 구상은 AI를 활용하여 초기 단계의 R&D 및 임상 개발을 강화하여 신약 개발을 가속화하고 관련 비용을 절감하기 위한 회사의 노력을 강조합니다.

2025년 1월 8일, Advanced Micro Devices Inc.(AMD)는 AI를 활용한 Drug Discovery 활동을 강화하기 위해 Absci Corp에 2,000만 달러를 투자했습니다. 이 제휴는 AMD의 첨단 컴퓨팅 역량을 활용해 바이오의약품의 혁신을 가속화하고 비용을 절감하는 것을 목표로 하며, 전통적인 의약품 개발 프로세스를 혁신하는 데 있으며, AI의 역할이 커지고 있음을 보여줍니다.

세계의 AI 활용 Drug Discovery 및 임상시험 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 개요

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter's Five Forces 분석
• PEST 분석

제4장 AI 활용 Drug Discovery 및 임상시험 시장 분석 : 컴포넌트별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 서비스
• 소프트웨어 솔루션
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제5장 AI 활용 Drug Discovery 및 임상시험 시장 분석 : 용도별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 임상시험
• 의약품 설계
• 데이터 집약이라고 분석
• 약물 특성 평가
• 바이오마커 연구
• 기타
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제6장 AI 활용 Drug Discovery 및 임상시험 시장 분석 : 치료 영역별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 종양
• 심혈관질환
• 감염증
• 신경변성질환
• 대사성 질환
• 면역 질환
• 기타
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제7장 AI 활용 Drug Discovery 및 임상시험 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 제약·바이오의약품 기업
• 수탁 연구기관(CRO)
• 학술기관 및 연구 센터
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제8장 AI 활용 Drug Discovery 및 임상시험 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이·예측

제9장 북미의 AI 활용 Drug Discovery 및 임상시험 시장 분석

• 미국
• 캐나다

제10장 유럽의 AI 활용 Drug Discovery 및 임상시험 시장 분석

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 러시아
• 기타

제11장 아시아태평양의 AI 활용 Drug Discovery 및 임상시험 시장 분석

• 중국
• 일본
• 인도
• 호주
• 한국
• 싱가포르
• 기타

제12장 라틴아메리카의 AI 활용 Drug Discovery 및 임상시험 시장 분석

• 브라질
• 멕시코
• 아르헨티나
• 콜롬비아
• 기타

제13장 중동 및 아프리카의 AI 활용 Drug Discovery 및 임상시험 시장 분석

• 남아프리카공화국
• 기타

제14장 기업 개요

• 경쟁 환경 분석
• 전략적 전망 분석
• Recursion
• Insilico Medicine
• BenevolentAI
• Saama Technologies
• Tempus
• Unlearn.ai, Inc.
• PathAI, Inc.
• Atomwise Inc.
• Schrodinger, Inc.
• AiCure
• Aitia

제15장 결론·제안

• Visiongain의 결론
• 참여 기업에 대한 제안

영문목차

The global AI-Enabled Drug Discovery and Clinical Trials market is projected to grow at a CAGR of 24.1% by 2035.

The AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Accelerated Drug Development Timelines and Cost Efficiency Driving Market Growth

Key drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth.

For instance:

On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets.

On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs.

On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes.

However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these regions.

Regulatory and Data Integration Challenges to Hamper Market Growth

While the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled platforms.

Ensuring real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical trials.

What Questions Should You Ask before Buying a Market Research Report?

• How is the AI-enabled drug discovery and clinical trials market evolving?
• What is driving and restraining the AI-enabled drug discovery and clinical trials market?
• How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the AI-enabled drug discovery and clinical trials projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market?
• Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the AI-Enabled Drug Discovery and Clinical Trials market today, and over the next 10 years:

• Our 285-page report provides 107 tables and 155 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI-Enabled Drug Discovery and Clinical Trials prices and recent developments.

Segments Covered in the Report

• Component
• Services
• Software Solutions
• Application
• Clinical Trials
• Drug Design
• Data Aggregation and Analysis
• Drug Characterisation
• Biomarker Research
• Others
• Therapeutic Area
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Neurodegenerative Diseases
• Metabolic Diseases
• Immunological Disorders
• Others
• End-users
• Pharmaceutical & Biopharmaceutical Companies
• Contract Research Organisations (CROs)
• Academic Institutes and Research Centre

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Russia
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035, with a focus on this segment of these companies' operations.

• Leading companies profiled in the report
• AiCure
• Aitia
• Atomwise Inc.
• BenevolentAI
• Insilico Medicine
• PathAI, Inc.
• Recursion
• Saama Technologies
• Schrodinger, Inc.
• Tempus
• Unlearn.ai, Inc.

Overall world revenue for AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 in terms of value the market will surpass US$3,000 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 report help you?
• In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035, with forecasts for component, application, therapeutic area, and end-users each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 24 key national markets - See forecasts for the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Growing Focus on Personalized Medicine
    • 3.3.1.2 Advancements in Technology
    • 3.3.1.3 Growing Adoption of AI in Healthcare
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Limited Data Availability and Quality
    • 3.3.2.2 Integration with Existing Infrastructure
    • 3.3.2.3 Concerns over Data Privacy and Security
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Improved Patient Outcomes
    • 3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials
    • 3.3.3.3 Growing Collaborations and Partnerships
• 3.4 Regulatory Framework
• 3.5 Emerging Markets and Megatrends
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Bargaining Power of Suppliers
  • 3.6.2 Bargaining Power of Buyers
  • 3.6.3 Competitive Rivalry
  • 3.6.4 Threat of Substitutes
  • 3.6.5 Threat of New Entrants
• 3.7 PEST Analysis

4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component

• 4.1 Key Findings
• 4.2 Component Segment: Market Attractiveness Index
• 4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 4.4 Services
  • 4.4.1 Market Size by Region, 2025-2035 (US$ Million)
  • 4.4.2 Market Share by Region, 2025 & 2035 (%)
• 4.5 Software Solutions
  • 4.5.1 Market Size by Region, 2025-2035 (US$ Million)
  • 4.5.2 Market Share by Region, 2025 & 2035 (%)

5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application

• 5.1 Key Findings
• 5.2 Application Segment: Market Attractiveness Index
• 5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 5.4 Clinical Trials
  • 5.4.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.4.2 Market Share by Region, 2025 & 2035 (%)
• 5.5 Drug Design
  • 5.5.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.5.2 Market Share by Region, 2025 & 2035 (%)
• 5.6 Data Aggregation and Analysis
  • 5.6.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.6.2 Market Share by Region, 2025 & 2035 (%)
• 5.7 Drug Characterization
  • 5.7.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.7.2 Market Share by Region, 2025 & 2035 (%)
• 5.8 Biomarker Research
  • 5.8.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.8.2 Market Share by Region, 2025 & 2035 (%)
• 5.9 Others
  • 5.9.1 Market Size by Region, 2025-2035 (US$ Million)
  • 5.9.2 Market Share by Region, 2025 & 2035 (%)

6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area

• 6.1 Key Findings
• 6.2 Therapeutic Area Segment: Market Attractiveness Index
• 6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 6.4 Oncology
  • 6.4.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.4.2 Market Share by Region, 2025 & 2035 (%)
• 6.5 Cardiovascular Diseases
  • 6.5.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.5.2 Market Share by Region, 2025 & 2035 (%)
• 6.6 Infectious Diseases
  • 6.6.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.6.2 Market Share by Region, 2025 & 2035 (%)
• 6.7 Neurodegenerative Diseases
  • 6.7.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.7.2 Market Share by Region, 2025 & 2035 (%)
• 6.8 Metabolic Diseases
  • 6.8.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.8.2 Market Share by Region, 2025 & 2035 (%)
• 6.9 Immunological Disorders
  • 6.9.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.9.2 Market Share by Region, 2025 & 2035 (%)
• 6.10 Others
  • 6.10.1 Market Size by Region, 2025-2035 (US$ Million)
  • 6.10.2 Market Share by Region, 2025 & 2035 (%)

7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users

• 7.1 Key Findings
• 7.2 End-users Segment: Market Attractiveness Index
• 7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 7.4 Pharmaceutical & Biopharmaceutical Companies
  • 7.4.1 Market Size by Region, 2025-2035 (US$ Million)
  • 7.4.2 Market Share by Region, 2025 & 2035 (%)
• 7.5 Contract Research Organizations (CROs)
  • 7.5.1 Market Size by Region, 2025-2035 (US$ Million)
  • 7.5.2 Market Share by Region, 2025 & 2035 (%)
• 7.6 Academic Institutes and Research Centre
  • 7.6.1 Market Size by Region, 2025-2035 (US$ Million)
  • 7.6.2 Market Share by Region, 2025 & 2035 (%)

8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America AI-Enabled Drug Discovery and Clinical Trials Market Analysis

• 9.1 Key Findings
• 9.2 North America AI-Enabled Drug Discovery and Clinical Trials Market Attractiveness Index
• 9.3 North America AI-Enabled Drug Discovery and Clinical Trials Market by Country, 2025, 2030 & 2035 (US$ Million)
• 9.4 North America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Country
• 9.5 North America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 9.6 North America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 9.7 North America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 9.8 North America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 9.9 U.S. AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 9.10 Canada AI-Enabled Drug Discovery and Clinical Trials Market Analysis

10 Europe AI-Enabled Drug Discovery and Clinical Trials Market Analysis

• 10.1 Key Findings
• 10.2 Europe AI-Enabled Drug Discovery and Clinical Trials Market Attractiveness Index
• 10.3 Europe AI-Enabled Drug Discovery and Clinical Trials Market by Country, 2025, 2030 & 2035 (US$ Million)
• 10.4 Europe AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Country
• 10.5 Europe AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 10.6 Europe AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 10.7 Europe AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 10.8 Europe AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 10.9 Germany AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.10 UK AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.11 France AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.12 Italy AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.13 Spain AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.14 Russia AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 10.15 Rest of Europe AI-Enabled Drug Discovery and Clinical Trials Market Analysis

11 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Analysis

• 11.1 Key Findings
• 11.2 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Attractiveness Index
• 11.3 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market by Country, 2025, 2030 & 2035 (US$ Million)
• 11.4 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Country
• 11.5 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 11.6 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 11.7 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 11.8 Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 11.9 China AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.10 Japan AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.11 India AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.12 Australia AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.13 South Korea AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.14 Singapore AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 11.15 Rest of Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market Analysis

12 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Analysis

• 12.1 Key Findings
• 12.2 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Attractiveness Index
• 12.3 Latin America AI-Enabled Drug Discovery and Clinical Trials Market by Country, 2025, 2030 & 2035 (US$ Million)
• 12.4 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Country
• 12.5 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 12.6 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 12.7 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 12.8 Latin America AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 12.9 Brazil AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 12.10 Mexico AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 12.11 Argentina AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 12.12 Colombia AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 12.13 Rest of Latin America AI-Enabled Drug Discovery and Clinical Trials Market Analysis

13 MEA AI-Enabled Drug Discovery and Clinical Trials Market Analysis

• 13.1 Key Findings
• 13.2 MEA AI-Enabled Drug Discovery and Clinical Trials Market Attractiveness Index
• 13.3 MEA AI-Enabled Drug Discovery and Clinical Trials Market by Country, 2025, 2030 & 2035 (US$ Million)
• 13.4 MEA AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Country
• 13.5 MEA AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component
• 13.6 MEA AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application
• 13.7 MEA AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area
• 13.8 MEA AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users
• 13.9 GCC AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 13.10 South Africa AI-Enabled Drug Discovery and Clinical Trials Market Analysis
• 13.11 Rest of MEA AI-Enabled Drug Discovery and Clinical Trials Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2024
• 14.2 Strategic Outlook
• 14.3 Recursion
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2020-2024
    • 14.3.3.2 R&D, 2020-2024
  • 14.3.4 Product/Service Benchmarking
  • 14.3.5 Strategic Outlook
  • 14.3.6 SWOT Analysis
• 14.4 Insilico Medicine
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Product/Service Benchmarking
  • 14.4.4 Strategic Outlook
  • 14.4.5 SWOT Analysis
• 14.5 BenevolentAI
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Product/Service Benchmarking
  • 14.5.4 Strategic Outlook
  • 14.5.5 SWOT Analysis
• 14.6 Saama Technologies
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Product/Service Benchmarking
  • 14.6.4 Strategic Outlook
• 14.7 Tempus
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
    • 14.7.2.1 Business Segment Market Shares, 2024
  • 14.7.3 Product/Service Benchmarking
  • 14.7.4 Strategic Outlook
  • 14.7.5 SWOT Analysis
• 14.8 Unlearn.ai, Inc.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Product/Service Benchmarking
  • 14.8.4 Strategic Outlook
• 14.9 PathAI, Inc.
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Product/Service Benchmarking
  • 14.9.4 Strategic Outlook
• 14.10 Atomwise Inc.
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Product/Service Benchmarking
• 14.11 Schrodinger, Inc.
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2020-2024
    • 14.11.3.2 R&D, 2020-2024
    • 14.11.3.3 Business Segment Market Shares, 2024
  • 14.11.4 Product/Service Benchmarking
  • 14.11.5 Strategic Outlook
  • 14.11.6 SWOT Analysis
• 14.12 AiCure
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Product/Service Benchmarking
  • 14.12.4 Strategic Outlook
• 14.13 Aitia
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Product/Service Benchmarking
  • 14.13.4 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players